| Mara Lee Goebel, PHARMD | |
|
2401 Central Ave, Dodge City, KS 67801-6206 | |
| (620) 227-8193 | |
| (620) 227-8006 |
| Full Name | Mara Lee Goebel |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2401 Central Ave, Dodge City, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093306540 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-16838 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mara Lee Goebel, PHARMD 2401 Central Ave, Dodge City, KS 67801-6206 Ph: (620) 227-8193 | Mara Lee Goebel, PHARMD 2401 Central Ave, Dodge City, KS 67801-6206 Ph: (620) 227-8193 |
News Archive
New research reveals that people with obstructive sleep apnea (OSA) have a higher risk of developing gout, even beyond the first years after being diagnosed with the sleep disorder. The findings are published in Arthritis & Rheumatology, an official journal of the American College of Rheumatology.
Scientists from Northwell Health Laboratories have developed a new diagnostic multiplex assay that can be used for epidemiological surveillance and clinical management of COVID-19.
Skin plays a surprising role in helping regulate blood pressure and heart rate, according to scientists at the University of Cambridge and the Karolinska Institute, Sweden. While this discovery was made in mice, the researchers believe it is likely to be true also in humans.
In a research project aimed at understanding the effect of prolonged exercise on the heart, the Karolinska Institutet and the Swedish School of Sport and Health Sciences studied a group of competitors taking part in the Adventure Racing World Championship. The results show no evidence of cardiac fatigue despite the fact that this is a continuous endurance event lasting between five and seven days.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.
› Verified 3 days ago
Ms. Sara Jane Wilhite, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 N 14th Ave, Dodge City, KS 67801 Phone: 620-225-6140 Fax: 620-225-8813 | |
Krista Morrison, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2401 Central Ave, Dodge City, KS 67801 Phone: 620-227-8193 | |
Janine Kilian Forrest, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1801 N 14th Ave, Dodge City, KS 67801 Phone: 620-225-6095 Fax: 620-225-6578 | |
Jordan A Doan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2401 Central Ave, Dodge City, KS 67801 Phone: 620-227-8193 | |
Son Nhut Loi, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 N 14th Ave, Dodge City, KS 67801 Phone: 620-225-6140 | |
Mr. James Steven Mccrery, R.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1801 N 14th Ave, Dodge City, KS 67801 Phone: 620-225-6095 Fax: 620-225-6578 |